Differential redox proteomic profiles of serum from severe asthma patients after one month of benralizumab and mepolizumab treatment

被引:4
作者
Landi, C. [1 ]
Vantaggiato, L. [1 ]
Shaba, E. [1 ]
Cameli, P. [2 ]
Carleo, A. [3 ]
Alessandro, M. d' [2 ]
Bergantini, L. [2 ]
Bargagli, E. [2 ]
Bini, L. [1 ]
机构
[1] Univ Siena, Dept Life Sci, Funct Prote Lab, Siena, Italy
[2] Univ Siena, Dept Internal & Specialist Med, UOC Resp Dis & Lung Transplantat, Siena, Italy
[3] Hannover Med Sch, Dept Pulmonol, Hannover, Germany
关键词
Mepolizumab; Benralizumab; Redox proteomics; Serum; Severe eosinophilic asthma; APOLIPOPROTEIN-A-I; ALPHA MONOCLONAL-ANTIBODY; EOSINOPHILIC ASTHMA; OXIDATIVE STRESS; DOUBLE-BLIND; BRONCHOALVEOLAR LAVAGE; PULMONARY-FIBROSIS; SYSTEMIC-SCLEROSIS; PLACEBO; CERULOPLASMIN;
D O I
10.1016/j.pupt.2021.102060
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Mepolizumab and Benralizumab are biological drugs for severe asthma patients able to reduce moderate-tosevere exacerbation rate (peripheral eosinophilial % mepolizumab 1.6 +/- 1.2; benralizumab 0; p < 0.0001), improving the quality of life and lung function parameters (FEV1%: mepolizumab 87.1 +/- 21.5; benralizumab 89.7 +/- 15, p < 0.04). Here we report a preliminary redox proteomic study highlighting the level of oxidative burst present in serum from patients before and after one month of both treatments. Our results highlighted apolipoprotein A1 oxidation after Mepolizumab treatment, that could be related to HDL functionality and could represent a potential biomarker for the treatment. On the other hand, after one month of Benralizumab we detected higher oxidation levels of ceruloplasmin and transthyretin, considered an important oxidative stress biomarker which action help to maintain redox homeostasis.
引用
收藏
页数:7
相关论文
共 51 条
  • [1] Abonia JP, 2011, EXPERT REV CLIN IMMU, V7, P411, DOI [10.1586/ECI.11.27, 10.1586/eci.11.27]
  • [2] Precision medicine and precision health: Building blocks to foster a revolutionary health care model
    Akdis, Cezmi A.
    Ballas, Zuhair K.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (05) : 1359 - 1361
  • [3] Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma
    Bagnasco, Diego
    Ferrando, Matteo
    Varricchi, Gilda
    Puggioni, Francesca
    Passalacqua, Giovanni
    Canonica, Giorgio Walter
    [J]. FRONTIERS IN MEDICINE, 2017, 4
  • [4] Bel EH, 2014, NEW ENGL J MED, V371, P2434, DOI 10.1056/NEJMc1412892
  • [5] Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
    Bel, Elisabeth H.
    Wenzel, Sally E.
    Thompson, Philip J.
    Prazma, Charlene M.
    Keene, Oliver N.
    Yancey, Steven W.
    Ortega, Hector G.
    Pavord, Ian D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (13) : 1189 - 1197
  • [6] PI3K inhibitor treatment ameliorates the glucocorticoid insensitivity of PBMCs in severe asthma
    Bi, Jing
    Min, Zhihui
    Yuan, Honglei
    Jiang, Zhilong
    Mao, Ruolin
    Zhu, Tao
    Liu, Chunfang
    Zeng, Yuzhen
    Song, Juan
    Du, Chunling
    Chen, Zhihong
    [J]. CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 9 (01):
  • [7] A NONLINEAR WIDE-RANGE IMMOBILIZED PH GRADIENT FOR 2-DIMENSIONAL ELECTROPHORESIS AND ITS DEFINITION IN A RELEVANT PH SCALE
    BJELLQVIST, B
    PASQUALI, C
    RAVIER, F
    SANCHEZ, JC
    HOCHSTRASSER, D
    [J]. ELECTROPHORESIS, 1993, 14 (12) : 1357 - 1365
  • [8] Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
    Bleecker, Eugene R.
    FitzGerald, J. Mark
    Chanez, Pascal
    Papi, Alberto
    Weinstein, Steven F.
    Barker, Peter
    Sproule, Stephanie
    Gilmartin, Geoffrey
    Aurivillius, Magnus
    Werkstrom, Viktoria
    Goldman, Mitchell
    [J]. LANCET, 2016, 388 (10056) : 2115 - 2127
  • [9] A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting
    Cameli, Paolo
    Bergantini, Laura
    d'Alessandro, Miriana
    Perruzza, Marco
    Cekorja, Behar
    Perillo, Felice
    Massa, Evaluna
    Ruzza, Annamaria
    Fossi, Antonella
    Beltrami, Valerio
    Sestini, Piersante
    Bargagli, Elena
    [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2020, 181 (08) : 606 - 612
  • [10] Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study
    Castro, Mario
    Wenzel, Sally E.
    Bleecker, Eugene R.
    Pizzichini, Emilio
    Kuna, Piotr
    Busse, William W.
    Gossage, David L.
    Ward, Christine K.
    Wu, Yanping
    Wang, Bing
    Khatry, Deepak B.
    van der Merwe, Rene
    Kolbeck, Roland
    Molfino, Nestor A.
    Raible, Donald G.
    [J]. LANCET RESPIRATORY MEDICINE, 2014, 2 (11) : 879 - 890